Earnings ·
Spyre Therapeutics reported second quarter 2026 financial results on August 4, 2026, announcing a net loss of $36.2…
SYRESpyre Therapeutics, Inc.
Spyre Therapeutics reported second quarter 2026 financial results on August 4, 2026, announcing a net loss of $36.2 million compared to $36.7 million in the prior year period. The company raised $435.2 million in net proceeds from a public offering of common stock in April 2026, resulting in a cash position of $1.1 billion as of June 30, 2026. Research and development expenses increased to $65.5 million from $40.1 million year-over-year due to higher manufacturing and clinical trial costs. The company also recognized a $40.0 million gain on the sale of in-process research and development assets related to pegzilarginase rights sold to Immedica Pharma AB. Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies for inflammatory bowel disease and rheumatic diseases.